Irban OD 15 Tablet PR contains Ivabradine 15mg, a selective inhibitor of the If current in the sinoatrial node, used primarily for the management of chronic stable angina pectoris and heart failure with reduced ejection fraction. Ivabradine acts by reducing heart rate without affecting myocardial contractility or intracardiac conduction, thereby decreasing myocardial oxygen demand and improving exercise tolerance. It is indicated for patients who are in sinus rhythm with a resting heart rate above 70 beats per minute and who are either intolerant to or inadequately controlled by beta-blockers. Irban OD 15 is administered once daily, providing sustained release of Ivabradine to maintain consistent plasma levels and optimize therapeutic outcomes. Common adverse effects include bradycardia, luminous phenomena (phosphenes), and headache, which are generally mild and transient. Caution is advised in patients with conduction abnormalities, severe hypotension, or hepatic impairment. Irban OD 15 should not be used concomitantly with strong CYP3A4 inhibitors due to increased risk of adverse reactions. Regular monitoring of heart rate and clinical status is recommended to ensure efficacy and safety. This medication should be prescribed and used under the supervision of a qualified healthcare professional.